Contingency Management for Cannabis Use for Persons With HIV
Completed · Not applicable
Conditions studied: Marijuana, HIV Infections
In brief
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.
Key facts
- Study ID
- NCT04866004
- Run by
- The University of Texas Health Science Center at San Antonio
- People needed
- 25
- Starts
- 2021-08-01
- Expected to finish
- 2025-07-31
- Last updated by the study team
- 2025-09-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
- Self-report of cannabis use at least once per week in the 6-month period prior to consent
- Provide a positive urine toxicology (UTOX) screen for cannabis
- Not seeking treatment for cannabis use
- Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
- Ability and willingness to provide inform consent
- English fluency
You may not qualify if…
- Currently receiving treatment for cannabis or other drug use disorder
- Diagnosed or receiving treatment for a current major depressive or anxiety disorder
- Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
- Positive UTOX screen for opioids
- Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
Where it is running
- Center for Neurobehavioral Research on Addiction — Houston, Texas, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.